Skip to main content
Home / Current Drug Metabolism, Volume 15, Number 7

Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance

Buy Article:

$68.00 + tax (Refund Policy)

Authors: Hu, Yutong; Li, Chuangang; Li, Hong; Li, Molin; Shu, Xiaohong

Source: Current Drug Metabolism, Volume 15, Number 7, 2014, pp. 703-710(8)

Publisher: Bentham Science Publishers

Multi-drug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of tumors. Resveratrol, a natural product, may inhibit efflux transporters, such as P-glycoprotein (P-gp), multi-drug resistance-associated protein (MRP) and breast cancer resistance protein (BCRP), and could become a potential multi-drug-resistant regulator. But it remains unclear how resveratrol exerts its reversal effect. In this review, we attempt to reveal the interactions between resveratrol and ABC transporter proteins, and summarize the research profile of resveratrol’s reversal mechanisms, thus to provide pivotal information on the development and application of multi-drug resistance reversal agents.

Keywords: ATP binding cassette transporters; P-glycoprotein; breast cancer resistance protein; multi-drug resistance; multi-drug resistance associated protein; resveratrol

Document Type: Research Article

Publication date: 01 September 2014

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content